Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Holdings Reduced by Suntrust Banks Inc.

Suntrust Banks Inc. reduced its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 14.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,156 shares of the biopharmaceutical company’s stock after selling 191 shares during the quarter. Suntrust Banks Inc.’s holdings in Regeneron Pharmaceuticals were worth $432,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Capital International Investors bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at $703,075,000. Capital World Investors grew its position in shares of Regeneron Pharmaceuticals by 5.3% in the third quarter. Capital World Investors now owns 6,384,323 shares of the biopharmaceutical company’s stock valued at $2,579,522,000 after purchasing an additional 322,051 shares in the last quarter. Morgan Stanley grew its position in shares of Regeneron Pharmaceuticals by 70.6% in the third quarter. Morgan Stanley now owns 464,603 shares of the biopharmaceutical company’s stock valued at $187,719,000 after purchasing an additional 192,236 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Regeneron Pharmaceuticals by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 1,078,453 shares of the biopharmaceutical company’s stock valued at $402,138,000 after purchasing an additional 78,143 shares in the last quarter. Finally, Vanguard Group Inc grew its position in shares of Regeneron Pharmaceuticals by 1.3% in the third quarter. Vanguard Group Inc now owns 5,754,927 shares of the biopharmaceutical company’s stock valued at $2,325,220,000 after purchasing an additional 75,868 shares in the last quarter. Institutional investors and hedge funds own 66.97% of the company’s stock.

In other news, major shareholder Sanofi sold 131,115 shares of the business’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $412.17, for a total value of $54,041,669.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 12.42% of the stock is currently owned by corporate insiders.

Shares of REGN traded down $3.68 during midday trading on Wednesday, reaching $340.46. The stock had a trading volume of 770,781 shares, compared to its average volume of 751,683. Regeneron Pharmaceuticals Inc has a 12-month low of $281.89 and a 12-month high of $442.00. The company has a current ratio of 4.47, a quick ratio of 3.67 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $37.20 billion, a P/E ratio of 17.19, a PEG ratio of 1.29 and a beta of 1.18.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, February 6th. The biopharmaceutical company reported $6.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.10 by $1.74. Regeneron Pharmaceuticals had a return on equity of 29.77% and a net margin of 36.43%. The firm had revenue of $1.93 billion during the quarter, compared to analysts’ expectations of $1.73 billion. During the same period in the prior year, the business earned $5.23 EPS. The company’s revenue for the quarter was up 21.9% compared to the same quarter last year. On average, equities research analysts predict that Regeneron Pharmaceuticals Inc will post 19.92 EPS for the current year.

Several equities analysts have recently weighed in on the company. BidaskClub upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 1st. Cantor Fitzgerald reiterated a “hold” rating and issued a $441.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, February 6th. Piper Jaffray Companies lifted their price target on Regeneron Pharmaceuticals to $487.00 and gave the company an “overweight” rating in a research report on Tuesday, February 26th. TheStreet upgraded Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Thursday, January 17th. Finally, Guggenheim cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $466.00 to $425.00 in a research report on Friday, February 22nd. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $413.94.

ILLEGAL ACTIVITY NOTICE: “Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Holdings Reduced by Suntrust Banks Inc.” was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.baseballdailydigest.com/news/2019/04/24/regeneron-pharmaceuticals-inc-regn-stake-lowered-by-suntrust-banks-inc.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: Analyzing a company’s cash flow statement

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.